Vicente Anido (University of West Virginia via YouTube)

Aerie fires CEO af­ter lead pro­gram flop, com­ments about pri­ma­ry end­points be­ing 'not re­quired'

Aerie Phar­ma­ceu­ti­cals CEO Vi­cente Anido has left the com­pa­ny less than a week af­ter try­ing to chart a Phase III study in the wake of a se­ri­ous Phase IIb flop.

Anido’s last day at Aerie was Fri­day, the biotech an­nounced in a news re­lease Tues­day morn­ing, and Ben­jamin Mc­Graw is tak­ing his place in an in­ter­im role. The now for­mer CEO was ter­mi­nat­ed with­out cause, ac­cord­ing to an SEC fil­ing.

The board has start­ed look­ing for a full-time chief to take his place.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.